Edward F. Weston Medal for Professional Achievement

Clifford M. SamuelClifford M. Samuel ‘88
Vice President, Access Operations & International Access Operations

Clifford Samuel is Vice President of Access Operations & Emerging Markets, which includes Africa, Latin America, the Caribbean, Central and Southeast Asia.  Under his leadership, he oversees the development and management of innovative manufacturing, distribution and business models to make the company’s medicines available at affordable prices in more than 130 countries.  In addition to coordinating Gilead’s internal operations on access and emerging markets, Samuel develops and maintains strategic partnerships around the world, including collaborations with governments, non-governmental organizations and 15 drug manufacturers in India with licenses to provide Gilead medicines in resource-constrained countries hardest hit by the HIV/AIDS epidemic. Samuel joined Gilead in 1996.  Prior to his appointment to what was Gilead’s International Access Operations, he held management and leadership positions on the National Accounts and Commercial Operations teams.

Samuel joined Gilead in March of 1996 as a therapeutic specialist.  In 2001, he was promoted to National Accounts Manager (NAM), where he developed and exponentially expanded the NAM team into three distinct divisions in order to keep pace with Gilead’s growth within the antiviral marketplace.  He was later promoted to senior director of national accounts.  In 2004, he was appointed as Gilead’s senior director of commercial operations, where he focused on expanding critical business functions in areas such as analytics and forecasting, business operations and contract compliance, market research, training and development. In January of 2010, Samuel was promoted to vice president of International Access Operations.

Samuel has presented frequently on the use of market-based approaches to enhance global access to HIV medications, including at the 2010 PharmAsia Summit and the 2011 Virology Futures conference.  He was invited to speak at the Stanford University School of Medicine’s Access and Delivery of Essential Medicines program, and most recently served as a panelist at a forum co-sponsored by UNITAID, UNAIDS and the Medicines Patent Pool at the 2011 United Nations General Assembly High Level Meeting on AIDS. Samuel is the lead author of an abstract describing the evolution of Gilead’s global access efforts being presented at the 2011 International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Prior to joining Gilead Sciences, Samuel was a sales representative at ICI Pharmaceuticals, focusing on the cardiovascular market. Following his tenure at ICI, he joined Glaxo Pharmaceuticals in 1992, where he represented various products in the antibiotic, CNS, oncology and respiratory markets. In 1995, Samuel was promoted to Glaxo’s HIV/Oncology Specialty Division, where he launched 3TC and represented AZT.

Samuel is a member of the Albert Dorman Honors College Board of Visitors.  He received his bachelor’s degree in mechanical engineering from NJIT, and was awarded the Edward F. Weston Medal for Professional Achievement by the university in 2010.